Dr. Maxensia Owor, MBChB, MMed (Paed), MPH
Dr Maxensia Owor is an Investigator at MU-JHU Research Collaboration. She is a paediatrician and over the last 20 years has conducted several studies in prevention of Mother to Child transmission of HIV and paediatric clinical trials on treatment of HIV infected children. Recently Dr. Owor has also been involved in clinical trials of HIV prevention among HIV negative breastfeeding women. Her areas of interest include prevention of mother to child transmission of HIV and paediatric HIV.
Click link for publications bit.ly/3mCu3Oi
Dr. Deo Wabwire (MBChB, MMed Internal Medicine
Dr Deo Wabwire is an internist at MU-JHU. He has been involved in perinatal HIV prevention studies since 2002 and more recently pharmacokinetic studies in pregnant women. He has been a co-investigator for multiple NIH network supported studies [including IMPAACT 1078(TB APPRISE), HPTN046 and PROMISE; antiretroviral therapy for perinatal HIV prevention]. He was the medical director for the MTCT plus antiretroviral treatment program and has continued to provide HIV care and treatment for mothers enrolled in the different perinatal and maternal HIV prevention and treatment trials at MU-JHU. He served as co-director and senior mentor for the Stephen Lewis funded mentorship program providing mentorship in HIV care and treatment to health care providers across Africa.
He is currently the Investigator of Record for IMPAACT 1026s, pharmacokinetics of antiretroviral and TB drugs in HIV infected pregnant women as well as IOR for IMPAACT 2010; Dolutegravir for prevention of mother to child HIV transmission.
Click link for publications bit.ly/2RkctTs
Dr. Linda Barlow-Mosha, MD MPH
Dr Linda Barlow- Mosha is a Paediatrician and Senior Investigator at Makerere University-Johns Hopkins University Research Collaboration (MU-JHU) in Kampala, Uganda with over 15 years of experience. She heads the HIV paediatric, adolescent and youth research domain. Dr Barlow-Mosha leads a varied portfolio of research that addresses critical scientific questions in pediatric HIV care and treatment as well as birth defects surveillance. She is the Senior Program manager of the Birth Defect Surveillance Project in Uganda.
Dr. Barlow-Mosha has been involved in development of international and national guidelines for HIV prevention, care, and treatment and is a member of the IMPAACT HIV Scientific Treatment Committee. Her clinical and research interests are in complications of pediatric HIV infection, antiretroviral drug resistance and pharmacokinetics, birth defects, and learning disabilities. Dr Barlow-Mosha received her training from Johns Hopkins University (BA, and MPH), Howard University (MD), and Thomas Jefferson University (Paediatrics). Click Link for publications bit.ly/3s517Q4
Dr. Eric Wobudeya (MB ChB, MMed, MSc)
Dr. Eric Wobudeya is a consultant paediatrician at Mulago National Referral Hospital (Kampala, Uganda) and an investigator at Makerere-Johns Hopkins University Research Collaboration (MU-JHU), Kampala. Over the past 17 years he has been a practicing clinician and an active research investigator for the last 12 years. His research has been focused on pediatric tuberculosis (TB) and gastroenterology. He is the Head of the Mulago National Referral Hospital Paediatric TB Unit where he has established a stable paediatric TB cohort. He is the current Chair of the National Pediatric TB Technical working group that advises the Uganda National TB & Leprosy program on Paediatric TB care.
Click link for publications bit.ly/2PO2gyx
Dr. Carol Onyango (MBChB, MSc)
Dr Carol Onyango is the MU-JHU CRS Coordinator. She has been the overall, cross-study/cross-Network coordinator for the CRS IMPAACT, ACTG, HPTN, and MTN studies. She serves as a link between DAIDS and the site related to DAIDS-related trainings or meetings, e.g., DAERS, Protocol Registration Training, Informed Consent Review, etc. She is responsible for integrating cross-Network activities. She is involved in staff protocol trainings and serves as a resource for the individual study coordinators. She assists with annual reports and other protocol-related deadlines in order to ensure that all research is conducted according to DAIDS and network policies. As the IoR for P1078, she successfully completed enrollment and follow up of 166 HIV-infected pregnant and postpartum women randomized to isoniazid/placebo prophylaxis. Currently she is the IoR for the PHOENIx study (ACTG co-sponsored by IMPAACT). She supports the study coordinators and PIs to ensure follow up of monitor visits, timely progress reports, IRB submissions, and protocol registration. She also supports PIs with coordination of DAIDS-related correspondence, e.g., completion of site surveys and target projections and
Dr. Musa Sekikubo, MBChB, MMED (Obs/Gyn), PhD (Infection Biology)
Dr Musa Sekikubo is a Senior Lecturer of Obstetrics and Gynaecology, School of Medicine, Makerere University, Kampala Uganda and an independent consultant for the Makerere University-Johns Hopkins University Research Collaboration (MU-JHU), Kampala. He is the local Principal Investigator of Sero-epidemiology of maternally derived antibodies against group B Streptococcus (funded by Bill and Melinda Gates foundation), preparatory work for GBS maternal vaccine trials (EDCTP-funded) and Clinical manifestation of Covid-19 among pregnant women.
Since 2006, Dr. Sekikubo has been an active clinician mentored undergraduate and post graduate students and has intensified clinical research after his graduation from Karolinska Institute with a doctorate in infection biology. He currently supervises two doctoral students in the thematic areas of maternal vaccination and vaginal microbiota. He also offers supportive roles to MTN studies that are conducted in Kawempe National Referral Hospital. His main interest is research on maternal immunization to reduce maternal morbidity and improve neonatal outcomes.
Dr. Brenda Gati Mirembe, MBChB, MSc Epidemiology
Dr Brenda Gati Mirembe is a medical doctor and senior Investigator for MU-JHU CARE LTD, Kampala. She has over 10 years’ experience in research conduct most especially in area of Primary HIV prevention among adolescent girls and women. Her vast experience in research conduct led her to being selected to be part of the DAIDS Advisory Research Training committee as a trainer for upcoming researchers in the region at DAIDS training meeting that was held in Johannesburg in 2019.
She has worked on a number of studies looking at various PrEP products for HIV prevention under the Microbicide Trials Network (MTN) and HIV Prevention Trials Network (HPTN) portfolios in various capacities. She was part of the MTN020/ASPIRE trial that found a monthly Dapivirine vaginal ring to be effective in prevention of HIV acquisition among women and the HPTN084 trial that has demonstrated effectiveness of long acting Cabotegravir injection for HIV prevention among women. Brenda continues to be part of research team under the women’s health domain led by Dr Clemensia to conduct trials assessing safety of the Dapivirine vaginal ring and oral Truvada among vulnerable populations like pregnant and breastfeeding women who are also at substantial risk for HIV acquisition. Research is ongoing to look at safety of long acting cabotegravir injection among adolescent girls. Even with the breakthroughs seen so far in HIV prevention research, there is need for more options as not one size fits all.A recent partnership with Merck Sharp & Dohme Corp(MSD) and University of Washington will see MU-JHU conduct research on safety and effectiveness of a once monthly PrEP pill for HIV prevention among cisgender females.
Dr. Mirembe’s passion is to see more diverse products for HIV prevention that women can choose from to include multipurpose technologies. Products that can empower women and young girls take control of their life and sexual health and control acquisition of sexually transmitted infections in general.Click link for publications bit.ly/3dUtMSX
Dr. Carolyne Agwau Akello, MBChB (MUK), MSc (Epidemiology)
Dr Carolyne Agwau Akello is an Investigator with the MTN-034/REACH Adolescent study and sun-investigator in a number of HIV prevention studies at MU-JHU. She is a medical doctor and a trained Epidemiologist from the London School of Medicine and Tropical Hygiene (LSHTM) with over 10 years’ experience in HIV/AIDS research with a focus on HIV prevention among women of reproductive age including adolescent girls and young women whom she is so passionate about.
Dr. Akello She is excited about the current HIV prevention landscape and hopeful that recent breakthroughs like the Dapivirine vaginal ring led by the Microbicides Trials Network (MTN), and products in development like injectable Cabotegravir etc. can be made available to populations at risk of HIV acquisition making the possibility of ending HIV in our generation a reality!
Click link for publications bit.ly/2QlU9Jq
Prof. Kirsty Le Doare, BA (Hons.), MBBS, PGHCE, MSc (Oxon), PhD FRCPCH
Dr. Kirsty Le Doare is a Professor of Vaccinology and Immunology At St. George’s, University of London seconded to MRC/UVRI@LSHTM research unit, Uganda and chief investigator for the SGUL@MUJHU maternal vaccines and seroepidemiology of Group B Streptococcus (GBS) studies. She is the chair of the DNDi/WHO maternal and neonatal health COVID19 working group and is a WHO scientific advisor for maternal vaccination. She has over 10 years of experience investigating the interactions between hosts and pathogens during the neonatal period, particularly Group B Streptococcus (GBS).
Dr. Kirsty completed an economics degree at the London School of Economics and worked for NGOs for 10 years prior to changing track to medical research. Her MSc at Oxford, PhD and postdoctoral work at Imperial College continued her interest in understanding why some babies get very ill and die from GBS disease and how we can harness protection transferred from mother to her baby via the placenta and in breastmilk. Her groups in Uganda and the UK use a variety of approaches to study GBS and other neonatal pathogens such as E. coli and Klebsiella, ranging from clinical studies and whole genome sequencing, to in vitro and in vivo models.
Clink link for publications bit.ly/3uAZrPY
Dr. Emily Namara Lugolobi (MBCHB, MPH)
Dr Emily Namara Lugolobi is the Program Coordinator for the HIV Care and Prevention Program at MU-JHU. This program currently takes care of over 2,500 clients at the MU-JHU ART Clinic and about 1,000 clients at Kawempe National Referral Hospital. She is a Public Health Specialist with over 10 years’ experience in the care and management of HIV/AIDS. She is committed to improving the lives of those infected affected with HIV and elimination of Mother to Child Transmission of HIV through implementation of evidence based practices. She has in the past coordinated a pilot Electronic Medical Records Project with the aim of improving Maternal and Child Health Services. She is interested in programming activities geared at achieving an HIV free generation and scaling up the use of Electronic Medical Records to improve health Service delivery in public institutions.
Dr. Flavia Matovu Kiweewa, MBChB, M.Sc., Ph.D. (Candidate)
Dr Flavia Matovu Kiweewa is a physician currently working as a Senior Research Scientist/ Investigator with Makerere University - Johns Hopkins University (MU-JHU) Research Collaboration, an Honorary Lecturer with Makerere University School of Public Health in Kampala- Uganda, and a concluding Ph.D. Fellow at the Wits School of Public Health, South Africa. She was the Site Lead Investigator at the highest enrolling site of the groundbreaking MTN-020/ASPIRE study, a phase III microbicide trial protocol evaluating the ‘’Safety and Effectiveness of a Vaginal Matrix Ring Containing Dapivirine for the Prevention of HIV-1 Infection in Women’’.
She is a Principal Investigator on an NIH sponsored R01 in bone health. She is also leading an Investigator sponsored Phase IV trial with the overall goal of optimizing bone health in HIV infected women. More recently, she received the 2019/ 2020 prestigious Gilead Global Public Health Award in Viral Hepatitis, a grant that’s evaluating perinatal outcomes among HIV infected women co-infected with hepatitis B (HBV).
Click for publications bit.ly/2RvwQNJ
Dr. Irene Lubega, MBChB, DTM & H, M.MED
She is a consultant paediatrician with over 20 years of experience working a Mulago National Referral Hospital and conducting research at MU-JHU. She has been an investigator in several HIV clinical trials that focused on prevention of mother to child transmission of HIV. These studies included among others, the NIH funded HIVNET012, HIVIGLOB/NVP, PROMISE Study and the P1092 study. She is currently the Co-PI for the MIRASOL study, a pathogen reduction study to improve blood safety.
Click link for publications bit.ly/3dSrbZK